Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Uterine cyclin A2–deficient mice as a model of female early pregnancy loss
Fatimah Aljubran, Katelyn Schumacher, Amanda Graham, Sumedha Gunewardena, Courtney Marsh, Michael Lydic, Kristin Holoch, Warren B. Nothnick
Fatimah Aljubran, Katelyn Schumacher, Amanda Graham, Sumedha Gunewardena, Courtney Marsh, Michael Lydic, Kristin Holoch, Warren B. Nothnick
View: Text | PDF
Research Article Reproductive biology

Uterine cyclin A2–deficient mice as a model of female early pregnancy loss

  • Text
  • PDF
Abstract

Proper action of the female sex steroids 17β-estradiol (E2) and progesterone (P4) on the endometrium is essential for fertility. Beyond its role in regulating the cell cycle, cyclin A2 (CCNA2) also mediates E2 and P4 signaling in vitro, but a potential role in modulating steroid action for proper endometrial tissue development and function is unknown. To fill this gap in our knowledge, we examined human endometrial tissue from fertile and infertile cisgender women for CCNA2 expression and correlated this with pregnancy outcome. Functional assessment of CCNA2 was validated in vivo using a conditional Ccna2 uterine-deficient mouse model, while in vitro function was assessed using human cell culture models. We found that CCNA2 expression was significantly reduced in endometrial tissue, specifically the stromal cells, from women undergoing in vitro fertilization who failed to achieve pregnancy. Conditional deletion of Ccna2 from mouse uterine tissue resulted in an inability to achieve pregnancy, which appeared to be due to alterations in the process of decidualization, which was confirmed using in vitro models. From these studies, we conclude that CCNA2 expression during the proliferative/regenerative stage of the menstrual cycle allows for proper steroid responsiveness, decidualization, and pregnancy. When CCNA2 expression levels are insufficient, there is impaired endometrial responsiveness, aberrant decidualization, and loss of pregnancy.

Authors

Fatimah Aljubran, Katelyn Schumacher, Amanda Graham, Sumedha Gunewardena, Courtney Marsh, Michael Lydic, Kristin Holoch, Warren B. Nothnick

×

Figure 4

Select impaired estrogen action in Ccna2d/d uteri.

Options: View larger image (or click on image) Download as PowerPoint
Select impaired estrogen action in Ccna2d/d uteri.
(A) Uterine wet weigh...
(A) Uterine wet weight at 0 hours (prior to treatment), 6, and 24 hours after E2 treatment. Different letters indicate statistical significance among the means for the treatment groups within treatment groups by 1-way ANOVA (block letters compare Ccna2fl/fl and italicized letters compare Ccna2d/d). ***P < 0.001 between genotypes within each treatment group (n = 6 mice/group). In A, a versus b = P < 0.05, a versus c = P < 0.01, b versus c = P < 0.05; a versus b = P < 0.05. (B) Gross uterine morphology and histology in Ccna2fl/fl and Ccna2d/d mice at 24 hours after E2 treatment. (C–H) E2 regulation of (C) Cstb, (D) Serpine1, (E) Timp1, (F) Timp3, (G) Fgf10, (H) Aqp5, and (I) Pgr transcripts between genotypes. Different block letters indicate statistical significance among the means for the Ccna2fl/fl treatment groups, while different letters in italics indicate statistically significant differences among the means in Ccna2d/d mice by 1-way ANOVA. In C and D, a versus b = P < 0.001, a versus b = P < 0.001; in E, a versus bc = P < 0.001, a versus b = P < 0.001; a versus c = P < 0.05, b versus c = P < 0.05; in F, a versus b = P < 0.05; in G, a versus b = P < 0.05; in H, a versus b = P < 0.05, a versus b = P < 0.05; in I, a versus b = P < 0.05, a versus b = P < 0.05. *P < 0.05; ***P < 0.001 between genotypes within each treatment group (n = 6 mice/group) by 2-tailed unpaired t test between genotypes. Within each graph of the box and whisker plot, X indicates the mean values while the whisker end points indicate the highest and lowest values.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts